<DOC>
	<DOCNO>NCT00717015</DOCNO>
	<brief_summary>We hypothesize subject CYP2D6*10 allele may lower steady state level endoxifen due reduce conversion tamoxifen endoxifen . Primary objective : - To determine steady state pharmacokinetics tamoxifen metabolites - To test effect genetic polymorphism CYP2D6 plasma concentration tamoxifen metabolites hormone receptor positive woman take tamoxifen adjuvant treatment breast cancer .</brief_summary>
	<brief_title>Tamoxifen Pharmacokinetics CYP2D6 Polymorphisms Asian Women With Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Signed informed consent . At least 18 year age . On tamoxifen least 3 month adjuvant therapy . On stable diet past 1 week blood sampling . Compliant tamoxifen medication . Completed adjuvant chemotherapy and/or adjuvant radiation therapy . â€¢ Patients list medication last 1 week accrual study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hormone Receptor Positive Breast Cancer</keyword>
</DOC>